Navigation Links
Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment
Date:6/17/2008

t be used to prevent diaper rash nor used for longer than 7 days because preventative use may not allow the treatment to work as well over time. If irritation occurs, or if the rash worsens, stop treatment and contact your healthcare provider.

About Barrier Therapeutics

Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(R) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: http://www.barriertherapeutics.com.

Xolegel, Vusion and Solage are registered trademarks of Barrier Therapeutics, Inc.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Contact: Barrier Therapeutics, Inc. 1-866-440-5508,

Kelly Sutt, 609-945-1235, ksutt@barriertherapeutics.com

Ruder Finn, Christoph Miller, 212-593-6495,

millerc@ruderfinn.com


'/>"/>
SOURCE Barrier Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Philadelphia Washed-Up ... Region Near Bottom
2. Bottomless bowls are an Ig Nobel winner
3. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
4. Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing
5. Free White Paper From The Beryl Institute Quantifies Bottom-Line Impact of Corporate Culture
6. Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line
7. Report: Life And Death Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S.
8. Mental Health & Addiction Among Working Parents & Children Affects the Bottom Line: Research Shows Staggering Economic Impact
9. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
10. New Report: Dangerous Drug Side Effects and Deaths Doubled Since 1998... Seniors Hit Hardest
11. New Report: Increasing Oregons Cigarette Tax Will Reduce Smoking, Save Lives and Save Money

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)..., , CHICAGO, Nov. 28 Ge...mon practice in the clinical routine when Siem...ientific Assembly and Annual Meeting of the Radiol...er 29 to December 3 at McCormick Place (Booth #825...o. With syngo. via , Siemens, new imaging ...
(Date:11/27/2009)..., , BEDFORD, Mass., Nov. 27 /PRNewswire-F...he "Company"), a supplier of precision technology ...d that an annual meeting of the Company,s sharehol.... The time and location of the meeting will be an...he Company received a requisition notice from Step...
(Date:11/27/2009)..., , SAN FRANCISCO, Nov. 27 /PRNewswire-Firs...) announced that Blair Lambert, CFO/COO, will pres... will be held at the May Fair Hotel in London, Eng.... GMT. ,, To listen to a live broadcast of The ...net, please log on to www.gymboree.com, click on "...
(Date:11/27/2009)... XenaCare Holdings has an...he Arthritis Foundation, one of the largest nonpro...and public health education. , ...- XenaCare Holdings, Inc. (OTCBB: XCHO), a company...tion of consumer healthcare products, has announce...
(Date:11/27/2009)... Voyant Health™ ann...ichigan) has licensed its TraumaCad Enterprise ort...nd workflow solution. , (...nnounced today that Spectrum Health (Grand Rapids,...rthopedic templating solution and its TraumaCad Ex...
Breaking Medicine News(10 mins):Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
... suggest some of these procedures may just be matt...ealthDay News) -- Premature births of single babie...cent years, and a new report finds that Caesarean ...," said Dr. Alan Fleischman, medical director and ...
...TER, Ill. Recent studies have linked sleep loss ...ression, obesity, diabetes, high blood pressure an...ill be presented and discussed by more than 5,000 ...ention Center from June 9 to 12. , More than 1,1...
...released today reveals a cellular mechanism involv... issue of The Journal of Neuroscience, shows that ...epilepsy, reduces alcohol intake in alcohol-depend...n involved in emotions such as stress and fear, is...
... than 40 years, Earth observing satellites have de...abled a better understanding and improved manageme...hese data are increasing daily as decision-makers ...In order to address these needs, ESA, the German S...
...d cholesterol test can help clinicians identify be...isk of heart disease, BIRMINGHAM, Ala., May 28 A...y announced it will be exhibiting its VAP,Choleste...the Moscone Convention Center in San Francisco., ...
...na, May 28 /Xinhua-PRNewswire-FirstCall/ -- China ...e Medical, or ,the Company,), a,manufacturer, mark...and,diagnostic products in China, today announced ...ver-the-Counter Bulletin,Board under the symbol ,C...
Other Medicine News:Health News:C-Sections Explain Jump in U.S. Preemie Births 2Health News:C-Sections Explain Jump in U.S. Preemie Births 3Health News:Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June 2Health News:Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June 3Health News:New study reveals brain cell mechanism of alcohol dependence 2Health News:European conference addresses increasing demand for EO data 2Health News:Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 2Health News:China Sky One Medical, Inc. Commences Trading on the American Stock Exchange 2
(Date:11/29/2009)...WA CITY, Iowa and ST. LOUIS, Nov. 29 /PRNewswire/ ...tative imaging software for the advanced analysis ...ies, a leader in minimally invasive delivery of in...panies have signed a definitive agreement covering...chial lung navigation and biopsy system. ,, "V...
(Date:11/29/2009)...GO, Nov. 29 Researchers using func...brain activation have found that men and women res... according to a study presented today at the annua...rica (RSNA). ,, "Men may direct more attention ...o process them in terms of implications for requir...
(Date:11/27/2009)...HICAGO, Nov. 27 At the upcoming Ra...meeting starting Sunday, Royal Philips Electronics...healthcare imaging and informatics solutions desig... and care providers, by delivering meaningful imag...odular price points and easy upgradability. This ...
Breaking Medicine Technology:VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 2VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 4New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4FDA Calls for Stricter Controls on Mercury Fillings 52981 1FDA Calls for Stricter Controls on Mercury Fillings 52981 2FDA Calls for Stricter Controls on Mercury Fillings 52981 3FDA Calls for Stricter Controls on Mercury Fillings 52981 4Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 1Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 2Viagra Trial for Sickle Cell Lung Problems Halted 52974 1Viagra Trial for Sickle Cell Lung Problems Halted 52974 2Viagra Trial for Sickle Cell Lung Problems Halted 52974 3
...PRINCETON, N.J., June 2 Medarex, Inc.,(Nasdaq: M...oing Phase 1,study of MDX-1106 (ONO-4538: developm...human anti-PD-1 antibody. Data presented from pati... in the study included the safety,tolerability and...In,addition, preliminary evidence of anti-tumor ac...
...- Randomized Phase II data show RAD001 significant...men with newly diagnosed hormone-positive breast ... studies suggest RAD001 may help overcome a major ...stuzumab, - Novartis to further explore potentia...initiating new trial in early 2009, EAST HANOVER,...
Other Medicine Technology:Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 2Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 3Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 4Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 5Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 6Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 7Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 8Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 9
CRP Full Range (0.1-160mg/l) Calibrator Series
CRP Calibrator (Multi-point, Liquid)
Fructosamine Controls Level 3
Drug Control Level 3
Medicine Products: